<DOC>
	<DOCNO>NCT02165007</DOCNO>
	<brief_summary>The study design Pilot trial reduce intensity Haploidentical HSCT patient sickle cell disease thalassemia . The purpose study assess safety toxicity reduce intensity condition haploidentical hematopoietic stem cell transplantation .</brief_summary>
	<brief_title>Haploidentical Hematopoietic Stem Cell Transplantation Children With Sickle Cell Disease Thalassemia Using CD34+ Positive Selected Grafts</brief_title>
	<detailed_description>Research subject undergo reduce intensity conditioning ( Hydroxyurea , ATG , Fludarabine , Thiotepa , Melphalan ) follow infusion peripheral blood stem cell graft collect haploidentical family donor CD34+ positively select use CliniMACS device . Sirolimus use GVHD prophylaxis give 9 month post-transplant taper one year The use CliniMACS device CD34 selection perform CNMC cross-reference master file CliniMACS CD34+ Reagent Milteyni Biotech ( BB-MF 8061 ) . CliniMACs electromechanical device intend isolate certain cell subset mixed cell population . When used combination CliniMACs CD34 reagent , possible prepare extremely pure population CD34+ cell upwards 5 log depletion contaminate T cell within close sterile system . We intend use system select cell HLA haploidentical related donor mobilize G-CSF prior stem cell collection . Since previous investigation strategy adult patient translate enhanced long term survival , intend limit protocol patient age 22 rapid immune reconstitution .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>First allogeneic transplant Age 22 year Patients severe sickle cell disease ( stroke , elevate TCD velocity , &gt; 2 acute chest syndrome , ongoing chronic red cell transfusion &gt; 6 month ) Patients transfusion dependent thalassemia evidence iron overload Patients must relate donor HLAmatched &gt; /=4 8 &lt; 8/8 HLAA , B , C DRB1 Cardiac function : Shortening fraction &gt; 25 % ; ejection fraction &gt; 40 % Estimated creatinine clearance great 50 mL/minute Pulmonary function : DLCO ≥40 % ( adjust hemoglobin ) FEV1≥50 % , oxygen saturation &gt; 91 % Liver function : direct ( conjugate ) bilirubin &lt; 2x upper limit normal ALT/AST &lt; 2.5x upper normal limit . Signed informed consent . Life expectancy le 6 month Patients uncontrolled bacterial , viral fungal infection ( undergo appropriate treatment progression clinical symptom ) within 1 month prior condition . Patients febrile illness suspect minor infection await clinical resolution prior start condition . Pregnant breastfeeding patient Patients seropositive human immunodeficiency virus ( HIV ) Patient active Hepatitis B C determine serology and/or NAAT Active hepatitis , bridge fibrosis cirrhosis liver biopsy ( biopsy require patient chronic transfusion therapy &gt; 1 year evidence iron overload ferritin &gt; 1000 ng/mL ) Patients suitable 8/8 HLA match related unrelated donor</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>